Royalty Pharma (RPRX) EBT Margin Growth (3y) (2022 - 2026)
Royalty Pharma (RPRX) EBT Margin Growth (3y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9,237.00 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 441.00 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -408.00 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 363.00 |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Royalty Pharma | 25.78 Bn | 28.22 Bn | - | -17.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.00 |
| Dec 31, 2025 | 16,505.00 |
| Sep 30, 2025 | 3,447.00 |
| Jun 30, 2025 | -7,606.00 |
| Mar 31, 2025 | 5,366.00 |
| Dec 31, 2024 | 4,700.00 |
| Sep 30, 2024 | 10,493.00 |
| Jun 30, 2024 | -10,919.00 |
| Mar 31, 2024 | -2,850.00 |
| Dec 31, 2023 | 5,631.00 |
| Sep 30, 2023 | -9,318.00 |
| Jun 30, 2023 | -5,254.00 |
| Mar 31, 2023 | 5,265.00 |
| Dec 31, 2022 | -42,402.00 |
| Sep 30, 2022 | -5,634.00 |
| Jun 30, 2022 | 5,266.00 |